FindTrial
Sign In

Evaluation of erdosteine effect on systemic inflamation biomarkers during COPD exacerbations - ERD/inflammation/COPD

Evaluation of erdosteine effect on systemic inflamation biomarkers during COPD exacerbations - ERD/inflammation/COPD

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2008-008529-32-IT
Enrollment
Unknown
Registered
2009-01-05
Start date
2009-01-08
Completion date
Unknown
Last updated
2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COPD exacerbation MedDRA version: 9.1 Level: SOC Classification code 10038738

Interventions

Trade Name: ERDOTIN Pharmaceutical Form: Capsule, hard INN or Proposed INN: Erdosteine Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 300-

Sponsors

U.O.PNEUMOLOGIA- AZ. USL1 DI MASSA E CARRARA
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: hospitalized patiens with COPD exacerbation Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: severe systemic clinic complications

Design outcomes

Primary

MeasureTime frame
Main Objective: evaluation of erdosteine activity on systemic inflammation during COPD exacerbation;Secondary Objective: evaluation of erdosteine activity on inflammation biomarkers;Primary end point(s): erdosteine activity on serum biomarkers of inflammation—

Countries

Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026